Novartis have been temporarily prevented from marketing its biosimilar version of Amgen’s drug Neupogen in the US. Earlier this year …

Novartis’ generic arm Sandoz has won the race to become the first company to market a biosimilar in the US …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

